/ Home
/ SUBMISSION

/ The BJOC
/ Diamond Open Access
/ Journal Statistics
/ Editorial Board
/ Community
/ Call for papers

/ Latest Articles
/ Most accessed
/ Thematic issues
/ Volumes
/ Authors

/ Alerts

/ TWITTER
/ LINKEDIN
/ Mastodon
/ RSS FEED

Empty search

Article Type

Publication Date Range

Search Tips

This search combines search strings from the content search (i.e. "Full Text", "Author", "Title", "Abstract", or "Keywords") with "Article Type" and "Publication Date Range" using the AND operator.

Search Examples

aromatic	the word “aromatic”
aromatic aldehyde	the word “aromatic” OR “aldehyde”
+aromatic +aldehyde	both words “aromatic” AND “aldehyde”
+aromatic -aldehyde	the word “aromatic” but NOT “aldehyde”
“aromatic aldehyde”	the exact phrase “aromatic aldehyde”
benz*	words which begin with “benz”, such as “benzene” or “benzyl”
benz*yl	words that begin with “benz” and end with “yl”, such as “benzyl” or “benzoyl”
benzyl~	words that are close to the word “benzyl”, such as “benzoyl” (i.e., fuzzy search)

BROWSE
Latest Articles
Most accessed
thematic issues
volumes
authors

BROWSE

Latest Articles Most Accessed Thematic Issues Volumes Authors

Author

2 article(s) from Cosford, Nicholas D P

Continuous-flow synthesis of highly functionalized imidazo-oxadiazoles facilitated by microfluidic extraction

Ananda Herath and
Nicholas D. P. Cosford

Beilstein J. Org. Chem. 2017, 13, 239–246, doi:10.3762/bjoc.13.26

PDF

Graphical Abstract

Scheme 1: In-flask (batch) preparation of imidazo[1,2-a]pyridin-2-yl-1,2,4-oxadiazoles (S1P₁ agonists) [27].

Jump to Scheme 1

Scheme 2: Gram-scale synthesis of mGlu₅ NAM by continuous flow in combination with microfluidic extraction.

Jump to Scheme 2

Scheme 3: Gram-scale synthesis of imidazo[1,2-a]pyridin-2-yl-1,2,4-oxadiazole S1P₁ agonist scaffold by contin...

Jump to Scheme 3

Album

Supp Info

Full Research Paper

Published 07 Feb 2017

Full text

Recent progress in the discovery of small molecules for the treatment of amyotrophic lateral sclerosis (ALS)

Allison S. Limpert,
Margrith E. Mattmann and
Nicholas D. P. Cosford

Beilstein J. Org. Chem. 2013, 9, 717–732, doi:10.3762/bjoc.9.82

PDF

Graphical Abstract

Figure 1: FDA-approved riluzole (1) and other ALS drugs currently in phase III clinical trials (2–6).

Jump to Figure 1

Figure 2: Riluzole (left) and prodrugs developed by McDonnell et al. [11].

Jump to Figure 2

Figure 3: Neurotransmitters N-acetyl-aspartyl glutamate (NAAG, top) and D-serine (bottom).

Jump to Figure 3

Figure 4: Thiopyridazines developed to increase EAAT2 protein levels.

Jump to Figure 4

Figure 5: Compounds shown to reduce SOD1 expression.

Jump to Figure 5

Figure 6: Families of compounds (named in italics) capable of reducing SOD1-induced cellular toxicity and mut...

Jump to Figure 6

Figure 7: Compounds identified by Nowak and co-workers [37] in silico that selectively bind SOD1 over human plasm...

Jump to Figure 7

Figure 8: 4-Aminoquinolines developed by Cassel and co-workers [43] for disruption of oligonucleotide/TDP-43 bind...

Jump to Figure 8

Figure 9: Cu(II)(atsm), an example of a Cu(II)(btsc) copper complex.

Jump to Figure 9

Figure 10: Pharmacological inducers of autophagy.

Jump to Figure 10

Figure 11: Compounds used to evaluate the effects of trophic factors on ALS disease progression.

Jump to Figure 11

Figure 12: Compounds identified as neuroprotective.

Jump to Figure 12

Figure 13: Compounds developed to reduce oxidative stress and inflammation.

Jump to Figure 13

Figure 14: Probes used to elucidate the roles of distinct gene-expression profiles in ALS patients.

Jump to Figure 14

Figure 15: Targets of potential therapeutics: This diagram illustrates the physiological targets of each compo...

Jump to Figure 15

Album

Supp Info

Review

Published 15 Apr 2013

Full text

Other Beilstein-Institut Open Science Activities

/ Help / Support & Contact / Alerts / Privacy Policy / Terms & Conditions / Impressum